Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|February 5, 2020
RA Quiz: Which tests are better suited for diagnosing rheumatoid arthritis?
In this month's rheumatoid arthritis quiz, we focus on tests used to diagnose rheumatoid arthritis as there are plenty. In this quiz, we focus on the most commonly ordered tests used to evaluate a patient who may have rheumatoid arthritis.
Advertisement
In this month's rheumatoid arthritis quiz, we focus on tests used to diagnose rheumatoid arthritis as there are plenty. In this quiz, we focus on the most commonly ordered tests used to evaluate a patient who may have rheumatoid arthritis.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement